Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
ABSTRACT Background Spinal muscular atrophy (SMA) is a motor neuron disease caused by mutations in the SMN1 gene. Nusinersen, an antisense oligonucleotide, has been shown to improve motor function in SMA patients. However, concerns regarding its renal safety remain as previous studies have linked si...
Saved in:
Main Authors: | Hüseyin Bahadır Şenol, Gizem Yıldız, Ayşe İpek Polat, Adem Aydın, Ayşe Semra Hız, Alper Soylu, Uluç Yiş |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Brain and Behavior |
Subjects: | |
Online Access: | https://doi.org/10.1002/brb3.70221 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of nusinersen on pulmonary function in children with spinal muscular atrophy in the plateau region: A pilot study
by: Jicai Zhu, et al.
Published: (2025-01-01) -
Assessment of proteinuria by urine dipstick as a predictive marker for dengue hemorrhagic fever in pediatric patients
by: Pornchanun Jarutunyaluk, et al.
Published: (2024-12-01) -
Reviews of spinal muscular atrophy in Taiwan
by: Yung-Hsiu Lu, et al.
Published: (2024-12-01) -
Advances in Nucleic Acid Drugs and Gene Therapies based on Animal Models of Duchenne Muscular Dystrophy
by: LIU Siyu, et al.
Published: (2024-12-01) -
Spinal muscular atrophy type 1 in the Caribbean: the first case report from the Dominican Republic
by: María Belén Martín-Sanz, et al.
Published: (2025-01-01)